EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Subcutaneous Levetiracetam Administration in Latino Patients on Home Care

Laura Cuellar-Valencia iD, Angelica Claros-Hulbert, Adriana Ortegon, Juliana Pino, Laura Velandia, Juan Esteban Correa-Morales iD

American Journal of Hospice and Palliative Medicine® · 2024

DOI: 10.1177/10499091231212450 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift American Journal of Hospice and Palliative Medicine®, 2024. Verfasst von Laura Cuellar-Valencia und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Universidad de La Sabana, Bogotá DC, Colombia. Hauptthemen laut MEDLINE: Anticonvulsants, Hispanic or Latino, Home Care Services, Levetiracetam. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Levetiracetam has a favorable pharmacology profile to be used subcutaneously. However, its subcutaneous use is still considered off-label as this is beyond its license. The evidence base for its safety, tolerability, and efficacy is limited to observational studies.

Objectives

To report the safety and efficacy of subcutaneous levetiracetam in Latino patients on home care.

Design

Observational retrospective case series study. Subjects: Consecutive sample of Latino adults with life-limiting illnesses.

Methods

A case series framework with 4 domains (selection, ascertainment, causality, and reporting) to ensure reporting quality was used. Additionally, 8 relevant outcomes established in a previous comprehensive review, were collected and reported. Adverse reactions were documented using the Common Terminology Criteria for Adverse Events.

Results

Fifteen Latino patients with oncological and non-oncological diagnoses received subcutaneous levetiracetam for a mean of 21 days on home care. Levetiracetam was most frequently initiated subcutaneously due to loss of the oral route. The average dosage of subcutaneous levetiracetam was 1200 mg. Only 1 patient required a dose adjustment, and only 2 patients experienced a total of 5 seizures during the therapy trial. No adverse reactions were reported.

Conclusions

Subcutaneous levetiracetam appears to be effective and safe. This case series of Latino patients in home care expands the evidence of its use in the home care setting. The preliminary data reported by now on multiple case series warrants robust trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsHispanic or LatinoHome Care ServicesLevetiracetamAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedInjections, SubcutaneousPiracetamRetrospective StudiesSeizures

Stichwörter der Autor:innen

home carelevetiracetampalliative careseizuresubcutaneous

Substanzen

AnticonvulsantsLevetiracetamPiracetam

Autor:innen und Institutionen

  • Faculty of Medicine, Universidad de La Sabana, Bogotá DC, Colombia.
  • Colombian National Cancer Institute, Bogotá DC, Colombia.
  • Forja home care IPS, Bogotá DC, Colombia.
  • Faculty of Medicine, Universidad del Bosque, Bogotá DC, Colombia.

ORCID-Profile: Laura Cuellar-Valencia, Juan Esteban Correa-Morales

Zitieren

APA

Cuellar-Valencia, L., Claros-Hulbert, A., Ortegon, A., Pino, J., Velandia, L., & Correa-Morales, J. E. (2024). Subcutaneous Levetiracetam Administration in Latino Patients on Home Care. American Journal of Hospice and Palliative Medicine®. https://doi.org/10.1177/10499091231212450

Vancouver

Cuellar-Valencia L, Claros-Hulbert A, Ortegon A, Pino J, Velandia L, Correa-Morales JE. Subcutaneous Levetiracetam Administration in Latino Patients on Home Care. American Journal of Hospice and Palliative Medicine®. 2024. doi:10.1177/10499091231212450

BibTeX
@article{CuellarValencia2024,
  author = {Cuellar-Valencia, Laura and Claros-Hulbert, Angelica and Ortegon, Adriana and Pino, Juliana and Velandia, Laura and Correa-Morales, Juan Esteban},
  title = {Subcutaneous Levetiracetam Administration in Latino Patients on Home Care},
  journal = {American Journal of Hospice and Palliative Medicine®},
  year = {2024},
  doi = {10.1177/10499091231212450}
}
Kostenlos starten →